Lung Cancer

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.

The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.

Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.

TTFields therapy, when given in addition to standard systemic therapy, improved overall survival in patients with metastatic non–small cell lung cancer.

Adagrasib elicited a 1-year overall survival rate of 52.8% and 2-year rate of 31.3%.

The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.

Oncology nurses can help patients with metastatic lung cancer find meaning in their experiences and potentially help them cope more effectively with their diagnosis.

The FDA has granted regular approval to pralsetinib as a treatment for adults with metastatic RET fusion-positive non-small cell lung cancer.

Patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions achieved a confirmed objective response rate of 38.4% with zipalertinib.

Overall survival data from the phase 3 ADUARA trial has further supported the use of osimertinib to treat EGFR-mutant non–small cell lung cancer in the adjuvant setting.

As evidence begins to mount supporting the efficacy of antibody-drug conjugates (ADCs), it is important that clinicians increase their knowledge of ADCs to improve the delivery of these agents.

The investigator-assessed progression-free survival was 9.0 months with sugemalimab plus chemotherapy arm vs 4.9 months with placebo plus chemotherapy.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Lazertinib reduced the risk of progression by 55% in patients with EGFR-mutated advanced non–small cell lung cancer compared with gefitinib.

Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.

The FDA has launched a priority review of repotrectinib based on data from the phase 1/2 TRIDENT-trial.

Frontline chemoimmunotherapy was associated with improved median overall survival, compared with chemotherapy alone, in patients with advanced non–small cell lung cancer.

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.

Pembrolizumab before and after resection improves event-free survival outcomes for patients with early-stage NSCLC, according to findings from KEYNOTE-671.

Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.

The addition of toripalimab to perioperative chemotherapy led to a statistically significant improvement in event-free survival for patients with non–small cell lung cancer.

The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.

Patients with TKI-naïve and crizotinib-pretreated ROS-positive non–small cell lung cancer continued to show responses to treatment with taletrectinib.

At a median follow-up of 33.3 months, the median overall survival was not evaluable with cemiplimab, vs 20.7 months with chemotherapy alone, in this patient subset.

In a subset of patients with KRAS G12C–mutated non–small cell lung cancer, adagrasib yielded an overall response rate of 68%.

Olanzapine demonstrated efficacy in improving appetite and weight gain in patients receiving cytotoxic chemotherapies.